OH-PROCTER-&-GAMBLE
2.12.2020 10:35:04 CET | Business Wire | Press release
Today, Procter & Gamble Oral Care unveils its newest packaging innovation across its leading toothpaste brands, Crest, Oral-B and Blend-a-med. This announcement increases the level of recyclability of its toothpaste tubes, as part of the P&G Ambition 2030 commitments of achieving 100% recyclable or reusable packaging.
The leading global oral care brands, Crest and Oral-B, and the European brand Blend-a-med, will start the switch in January 2021 and will continue until full conversion, by 2025.
Toothpaste tubes are used by millions of consumers every day; however, its multi-material construction poses a challenge for recycling facilities around the globe. The solution to this is the HDPE – High-Density Polyethylene – tube, which provides the same product protection as current tubes, and which has been certified by North American and European recycling bodies to be compatible with existing recycling technologies. These HDPE tubes can be recycled where collection programs exist.
For introducing the right solution and making its toothpaste tubes more sustainable, Procter & Gamble is in discussions with several HDPE tube suppliers and has already reached an agreement with Albéa to start using its proprietary Greenleaf Generation 2 tube technology, which enables the tubes to be recyclable wherever collection schemes are active. Greenleaf Generation 2 tubes are recognized by the North American Association of Plastic Recyclers (APR) as well as RecyClass and SUEZ.circpack® in Europe and can be recycled within the existing, effective HDPE bottles recycling stream.
To earn APR recognition, it was demonstrated that the toothpaste tubes could be converted into quality post-consumer HDPE resin, and then reused to make new plastic bottles.
RecyClass is an independent cross-industry platform that assesses material recyclability and provides specific recommendations on how to improve packaging design to fit current recycling technologies in Europe. The platform certifies that Procter & Gamble’s ‘toothpaste tube’ technology is considered to be compatible with HDPE recycling. Moreover, it certifies that both Procter & Gamble’s ‘toothpaste tubes with cap’ product will not have a negative impact on the current European HDPE containers recycling.
“Toothpaste tubes are not largely recyclable today; with the RecyClass certification for Albéa’s Greenleaf Generation 2 technology used by P&G, however, we are on the right track towards increasing both the design for recycling awareness for tubes as well as increasing recycling quality and rates for the HDPE rigids stream in Europe,” said Paolo Glerean, RecyClass Chairman.
In addition, the sortability of the tubes has been successfully tested by SUEZ.circpack® following the RecyClass sorting protocol, confirming that the tubes will flow into the correct stream and be recycled with the HDPE materials.
“Accurate sorting is an essential step to ensure recycling. That is why SUEZ.circpack® performed sorting tests in a fully operational sorting facility in Germany. The facility and the technologies in place are very common for the European recycling industry. The results showed that the packaging could be correctly sorted into the HDPE material flow. The recognition of the plastic with Near InfraRed (NIR) technology was accurate and consistent,” said Vincent Mooij, Head of SUEZ.circpack® .
“P&G Oral Care started our sustainability journey many years back and continue to reduce our footprint. To drive a more circular supply chain, all of our production sites globally are qualified as sending zero manufacturing waste to landfill, and our sites across the United States, Canada, and Europe purchase 100% renewable electricity,” stated Steve Bishop, P&G Health Care Chief Executive Officer. “There is much yet to be done; however, we are proud of the steps we are taking with our leading brands, Crest in North America, and Oral B and Blend-a-med in Europe, to achieve recyclable tubes in the years ahead.”
Virginie Helias, P&G’s Chief Sustainability Officer added: “We have committed to enable and inspire responsible consumption through innovation on our product and packaging. Our leading oral care brands touch millions of people around the world. This new packaging innovation will contribute to making the toothpaste tubes recyclable at scale in existing recycling streams, hence reducing our footprint and striving for circular solutions. It’s no longer about if or what we can do, but how quickly we can do it.”
About P&G:
P&G serves consumers around the world with one of the strongest portfolios of trusted, quality, leadership brands, including Always® , Ambi Pur® , Ariel® , Bounty® , Charmin® , Crest® , Dawn® , Downy® , Fairy® , Febreze® , Gain® , Gillette® , Head & Shoulders® , Lenor® , Olay® , Oral-B® , Pampers® , Pantene® , SK-II® , Tide® , Vicks® , and Whisper® . The P&G community includes operations in approximately 70 countries worldwide. Please visit http://www.pg.com for the latest news and information about P&G and its brands.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201201005391/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Kubota Vision Inc. Signs Supply and Licensing Agreement with Laboratoires KÔL for Stargardt Disease Treatment Candidate Under Compassionate Use4.5.2026 17:16:00 CEST | Press release
Kubota Vision Inc. (“Kubota Vision”), a wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Minato-ku, Tokyo, Japan) announced signing of a Supply and Licensing Agreement with Laboratoires KÔL (Clermont-Ferrand, France) for the provision of a Stargardt disease (STGD1) treatment candidate under compassionate use authorization. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260414590785/en/ The purpose of this Agreement is for Kubota Vision and KÔL to collaborate on providing “Emixustat” for treatment of Stargardt Disease (STGD1) through compassionate use authorization in France. Kubota Vision will exclusively manufacture and supply Emixustat final products to KÔL and KÔL will have exclusive rights to distribute Emixustat in France under compassionate use access. Ryo Kubota, Chairman, President, and CEO of Kubota Pharmaceutical Holdings, stated, “We are extremely pleased to enter into this Agreement with Labor
Incentive Market Set to Surpass $80B by 2030s — IMA Launches Tools to Help the Industry Keep Pace4.5.2026 16:28:00 CEST | Press release
With combined business spend on loyalty, employee recognition, and channel incentives projected to exceed $80 billion by the 2030s, the incentive industry is entering a period of rapid scale and strategic pressure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260422729016/en/ In response, the Incentive Marketing Association (IMA) launched a new suite of resources designed to help incentive professionals navigate an environment that’s becoming more specialized, fragmented, and central to business performance. “It’s not just more money coming in—it’s more complexity,” said Vince Chiofolo, President of the Incentive & Engagement Solution Providers (IESP). “Buyers are demanding programs that evolve fast, integrate deeply, and feel personal at scale. These new tools were built for that.” IMA’s Suite of Tools Includes: New Industry Report — Inside the Incentive Buyer’s Mind Drawn from insights of 50+ program owners, the report f
Tigo Energy Breaks Global Growth Benchmark; Boosts U.S. Energy Feature in Predict+4.5.2026 15:00:00 CEST | Press release
Advanced energy prediction platform adds real-time energy pricing for North American Independent System Operator (ISO) customers, accelerates meters-connected growth. Tigo Energy, Inc. (NASDAQ: TYGO) (“Tigo” or “Company”), a leading provider of intelligent solar and energy solutions, today announced that the Predict+ platform now offers integrated real-time spot market pricing for ISO customers in the United States. Predict+ provides utilities with deep insights into grid demand, renewable generation, and energy market dynamics, enhancing the precision, scalability, and robustness of energy forecasting to up to 97.5% accuracy through machine learning and artificial intelligence. For energy providers, Predict+ helps streamline operations, reduce volatility, and maximize performance. Predict+ empowers utility operators to adapt to real-world demand challenges when balancing renewable and baseload generation sources, particularly during extreme weather events and market disruptions. On th
Airship Announces 2026 Elevate Customer Experience Award Winners4.5.2026 15:00:00 CEST | Press release
Southwest Airlines, The Economist, and OneFootball among brands recognized at Elevate’26 Customer Experience Summit for setting the standard in mobile-first and AI-centered customer experiences Airship, the mobile-first customer experience company, today announced the winners of the 2026 Elevate Customer Experience Awards. Global brand leaders from The Economist, Southwest Airlines, and OneFootball were among those honored at the Elevate’26 Customer Experience Summit. The Elevate Awards spotlight global companies that have developed exceptional mobile-first customer experiences for their customers, created innovative campaigns, leveraged AI agents to reach new levels of productivity, and achieved real business results. "Evolving mobile-first consumer behaviors and unprecedented advancements in AI are driving a seismic shift that is reshaping how brands interact with their customers," said Brett Caine, CEO, Airship. "The 2026 Elevate Award winners aren’t just adapting, they’re leading t
Alnylam to Present New Analyses at Heart Failure 2026 Underscoring Consistent Clinical Profile of Vutrisiran in ATTR-CM4.5.2026 14:30:00 CEST | Press release
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced it will present new data analyses for vutrisiran in patients with the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) at Heart Failure 2026, a scientific congress of the European Society of Cardiology, taking place May 9-12, 2026, in Barcelona, Spain. ATTR-CM is a heterogeneous and rapidly progressive disease, and patients often present with complex clinical profiles. At Heart Failure 2026, Alnylam will present multiple new analyses from the Phase 3 HELIOS-B study of vutrisiran, which continue to support its use as a first-line treatment for patients with ATTR-CM, and further characterize its clinical profile across patients with a high disease burden, and in the context of concomitant therapies. Vutrisiran is the first and only transthyretin (TTR) silencer for ATTR-CM that delivers rapid knockdown of TTR at the source. Additional analyses being pr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
